» Articles » PMID: 31328614

Neuropeptide Y Reduces Expression of Social Fear Via Simultaneous Activation of Y1 and Y2 Receptors

Overview
Publisher Sage Publications
Specialty Pharmacology
Date 2019 Jul 23
PMID 31328614
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuropeptide Y (NPY) has anxiolytic effects and facilitates extinction of cued and contextual fear in rodents, thereby acting as a resilience factor against exaggerated fear responses after adverse events. We investigated whether NPY influences acquisition, expression and extinction of social fear in a mouse model of social fear conditioning (SFC).

Methods: NPY was administered intracerebroventricularly before SFC or before social fear extinction with or without prior administration of Y1 and/or Y2 receptor antagonists.

Results: We show that NPY affects SFC-induced social fear in a time point-dependent manner. When administered before SFC, NPY did not affect acquisition, expression and extinction of social fear. However, when administered before social fear extinction, NPY reduced expression of social fear via simultaneous activation of Y1 and Y2 receptors. As such, neither the Y1 receptor antagonist BIBO3304 trifluoroacetate nor the Y2 receptor antagonist BIIE0246 was able to block the effects of NPY completely. However, when administered in combination, they completely blocked the effects of NPY on social fear expression.

Conclusions: These findings have important clinical implications, as they suggest that although medication strategies aimed at increasing brain NPY activity are unlikely to prevent the formation of aversive memories after a traumatic social experience, they might improve the recovery from a traumatic social experience by reducing the expression of social fear.

Citing Articles

Development of Comorbid Depression after Social Fear Conditioning in Mice and Its Effects on Brain Sphingolipid Metabolism.

Zoicas I, Muhle C, Schumacher F, Kleuser B, Kornhuber J Cells. 2023; 12(10).

PMID: 37408189 PMC: 10216690. DOI: 10.3390/cells12101355.


Social Fear Affects Limbic System Neuronal Activity and Gene Expression.

Hamann C, Bankmann J, Mora Maza H, Kornhuber J, Zoicas I, Schmitt-Bohrer A Int J Mol Sci. 2022; 23(15).

PMID: 35897794 PMC: 9367789. DOI: 10.3390/ijms23158228.


Roles of Neuropeptides in Sleep-Wake Regulation.

Shen Y, Sun X, Li L, Zhang H, Huang Z, Wang Y Int J Mol Sci. 2022; 23(9).

PMID: 35562990 PMC: 9103574. DOI: 10.3390/ijms23094599.


Neuropeptide Y in the amygdala contributes to neuropathic pain-like behaviors in rats the neuropeptide Y receptor type 2/mitogen-activated protein kinase axis.

Yan W, Liu W, Wu J, Wu L, Xuan S, Wang W Bioengineered. 2022; 13(4):8101-8114.

PMID: 35313782 PMC: 9162000. DOI: 10.1080/21655979.2022.2051783.


Neuropeptide Y Reduces Social Fear in Male Mice: Involvement of Y1 and Y2 Receptors in the Dorsolateral Septum and Central Amygdala.

Kornhuber J, Zoicas I Int J Mol Sci. 2021; 22(18).

PMID: 34576305 PMC: 8472534. DOI: 10.3390/ijms221810142.


References
1.
Kornhuber J, Zoicas I . Neuropeptide Y prolongs non-social memory and differentially affects acquisition, consolidation, and retrieval of non-social and social memory in male mice. Sci Rep. 2017; 7(1):6821. PMC: 5533709. DOI: 10.1038/s41598-017-07273-x. View

2.
Blanco C, Bragdon L, Schneier F, Liebowitz M . The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2012; 16(1):235-49. DOI: 10.1017/S1461145712000119. View

3.
Fedoroff I, Taylor S . Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol. 2001; 21(3):311-24. DOI: 10.1097/00004714-200106000-00011. View

4.
Toth I, Neumann I, Slattery D . Social fear conditioning: a novel and specific animal model to study social anxiety disorder. Neuropsychopharmacology. 2012; 37(6):1433-43. PMC: 3327848. DOI: 10.1038/npp.2011.329. View

5.
Vezzani A, Sperk G, Colmers W . Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999; 22(1):25-30. DOI: 10.1016/s0166-2236(98)01284-3. View